Exagen Inc Stock Fundamentals
| XGN Stock | USD 4.05 0.05 1.22% |
Exagen Inc fundamentals help investors to digest information that contributes to Exagen's financial success or failures. It also enables traders to predict the movement of Exagen Stock. The fundamental analysis module provides a way to measure Exagen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Exagen stock.
At this time, Exagen's Depreciation And Amortization is very stable compared to the past year. As of the 25th of November 2024, Interest Expense is likely to grow to about 2.8 M, while Total Revenue is likely to drop about 32.2 M. Exagen | Select Account or Indicator |
Exagen Inc Company Shares Outstanding Analysis
Exagen's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Exagen Shares Outstanding | 17.64 M |
Most of Exagen's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Exagen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Exagen Shares Outstanding Historical Pattern
Today, most investors in Exagen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Exagen's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Exagen shares outstanding as a starting point in their analysis.
Exagen Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Exagen Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Exagen Inc has 17.64 M of shares currently outstending. This is 90.23% lower than that of the Biotechnology sector and 87.64% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 96.92% higher than that of the company.
Exagen Inc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Exagen's current stock value. Our valuation model uses many indicators to compare Exagen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Exagen competition to find correlations between indicators driving Exagen's intrinsic value. More Info.Exagen Inc is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Exagen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Exagen's earnings, one of the primary drivers of an investment's value.Exagen Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exagen's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exagen could also be used in its relative valuation, which is a method of valuing Exagen by comparing valuation metrics of similar companies.Exagen is currently under evaluation in shares outstanding category among its peers.
Exagen ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Exagen's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Exagen's managers, analysts, and investors.Environmental | Governance | Social |
Exagen Fundamentals
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.31) % | ||||
| Operating Margin | (0.17) % | ||||
| Current Valuation | 73.83 M | ||||
| Shares Outstanding | 17.64 M | ||||
| Shares Owned By Insiders | 29.74 % | ||||
| Shares Owned By Institutions | 57.21 % | ||||
| Number Of Shares Shorted | 52.21 K | ||||
| Price To Book | 5.62 X | ||||
| Price To Sales | 1.28 X | ||||
| Revenue | 52.55 M | ||||
| Gross Profit | 21.35 M | ||||
| EBITDA | (19.15 M) | ||||
| Net Income | (23.69 M) | ||||
| Cash And Equivalents | 76.39 M | ||||
| Cash Per Share | 4.70 X | ||||
| Total Debt | 23.72 M | ||||
| Debt To Equity | 0.55 % | ||||
| Current Ratio | 9.30 X | ||||
| Book Value Per Share | 1.33 X | ||||
| Cash Flow From Operations | (14.46 M) | ||||
| Short Ratio | 3.12 X | ||||
| Earnings Per Share | (0.94) X | ||||
| Target Price | 6.25 | ||||
| Number Of Employees | 174 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 72.31 M | ||||
| Total Asset | 56.94 M | ||||
| Retained Earnings | (279.22 M) | ||||
| Working Capital | 35.94 M | ||||
| Net Asset | 56.94 M |
About Exagen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Exagen Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exagen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exagen Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 2.3 M | 3.4 M | |
| Total Revenue | 52.5 M | 32.2 M | |
| Cost Of Revenue | 23.1 M | 15.4 M | |
| Stock Based Compensation To Revenue | 0.07 | 0.04 | |
| Sales General And Administrative To Revenue | 0.87 | 1.51 | |
| Research And Ddevelopement To Revenue | 0.09 | 0.09 | |
| Capex To Revenue | 0.02 | 0.02 | |
| Revenue Per Share | 2.97 | 2.82 | |
| Ebit Per Revenue | (0.43) | (0.46) |
Pair Trading with Exagen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.Moving against Exagen Stock
| 0.46 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.44 | KA | Kineta Inc | PairCorr |
| 0.42 | TCHH | Trustcash Holdings | PairCorr |
| 0.41 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.32 | EQ | Equillium | PairCorr |
The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.
The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Exagen Piotroski F Score and Exagen Altman Z Score analysis. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 3.163 | Quarterly Revenue Growth 0.066 | Return On Assets (0.17) | Return On Equity (0.70) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.